Literature DB >> 12215559

Increased tumor uptake of 3-(123)I-Iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study.

Tony Lahoutte1, Vicky Caveliers, Philippe R Franken, Axel Bossuyt, John Mertens, Hendrik Everaert.   

Abstract

UNLABELLED: 3-(123)I-Iodo-L-alpha-methyltyrosine (3-IMT) is an amino acid analog used for tumor imaging. Specific accumulation is mediated mainly by the system L amino acid transport system. System L activity is known to increase when cells are loaded with amino acids. The aim of our study was to measure the effects of amino acid preload on (123)I-3-IMT tumor uptake and image contrast in a rat tumor model using in vivo dynamic imaging.
METHODS: Rhabdomyosarcoma (R1M) tumor-bearing rats underwent 2 dynamic (123)I-3-IMT studies on separate days: 1 baseline study and 1 after intraperitoneal injection (0.25 mmol/kg) of a single amino acid (arginine, proline, glutamate, asparagine, tryptophan, or phenylalanine) administered 30 min before intravenous injection of 18.5 MBq (123)I-3-IMT. A (99m)Tc-labeled human serum albumin study was performed on each rat for the calculation of the blood-pool activity inside the tumor. Time-activity curves were generated for tumor, contralateral background region, kidney, heart, and total body. Tumor uptake was corrected for blood-pool and background activity. Image contrast was calculated as the ratio between tumor and background activity. The rate (K(1)) of tracer entering the tumor was obtained using Patlak analysis. A displacement study was performed on a separate group of rats, in which a high dose of phenylalanine was administered 40 min after (123)I-3-IMT injection.
RESULTS: (123)I-3-IMT accumulation in tumor reached a plateau 10 min after injection. Tumor uptake on the baseline scans correlated well with tumor size (r = 0.92). After preloading, tumor uptake and contrast increased in all conditions: arginine, +26% and +26%; proline, +15% and +13%; glutamate, +14% and +9%; asparagine, +19% and +15%; tryptophan, +36% and 11%; phenylalanine, +22% and + 13%. K(1) values also increased. Administration of an afterload with phenylalanine induced a significant displacement of (123)I-3-IMT tumor accumulation.
CONCLUSION: Prior amino acid administration increases (123)I-3-IMT tumor accumulation and image contrast. This effect can be explained by the increased antiporter activity of the amino acid transport system L in preloaded conditions. Our results indicate that the fasted state might not be the optimal metabolic condition to study tumor accumulation of L-transported tracers such as (123)I-3-IMT. Amino acid administration before (123)I-3-IMT injection could improve tumor uptake and image contrast.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215559

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues.

Authors:  T Vander Borght; S Asenbaum; P Bartenstein; C Halldin; O Kapucu; K Van Laere; A Varrone; K Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

Review 2.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

3.  T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control.

Authors:  Luca Mariotta; Tamara Ramadan; Dustin Singer; Adriano Guetg; Brigitte Herzog; Claudia Stoeger; Manuel Palacín; Tony Lahoutte; Simone M R Camargo; François Verrey
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

4.  Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas.

Authors:  Carina Stegmayr; Michael Schöneck; Dennis Oliveira; Antje Willuweit; Christian Filss; Norbert Galldiks; N Jon Shah; Heinz H Coenen; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-08       Impact factor: 9.236

5.  Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases.

Authors:  Shuntaro Oka; Masaru Kanagawa; Yoshihiro Doi; David M Schuster; Mark M Goodman; Hirokatsu Yoshimura
Journal:  Int J Mol Sci       Date:  2017-04-29       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.